Skip to main content

Table 6 GO categories of SUMO targeting genes with no expression changes during KSHV reactivation

From: The chromatin modification by SUMO-2/3 but not SUMO-1 prevents the epigenetic activation of key immune-related genes during Kaposi’s sarcoma associated herpesvirus reactivation

   

SUMO-2/3 12 h

SUMO-2/3 enriched at 12 hr

   

All genes

Gene expression no change

Gene expression no change

 

Pathway category

Genes in category

Genes identified

p-value

Genes identified

p-value

Genes identified

p-value

Pathogen-influenced signaling

Virus entry via endocytic pathways

99

31

1.41E-03

28

3.24E-03

20

5.13E-03

Cellular immune response

Antigen Presentation pathway

40

14

1.26E-02

12

3.63E-02

9

3.24E-02

 

CD40 signaling

70

23

2.82E-03

21

4.79E-03

14

1.91E-02

 

HMGB1 signaling

99

25

9.33E-02

24

6.46E-02

16

1.03E-01

 

IL-10 signaling

78

19

9.55E-02

16

2.07E-01

11

2.10E-01

 

IL-15 signaling

67

20

1.86E-02

19

1.55E-02

16

2.34E-03

 

IL-3 signaling

74

23

1.41E-02

22

1.02E-02

14

4.90E-02

 

IL-8 signaling

205

48

4.68E-02

44

6.92E-02

27

2.14E-01

 

NF-κB activation by viruses

82

23

2.00E-02

21

3.16E-02

15

3.39E-02

 

p38 MAPK signaling

117

26

3.80E-01

24

3.88E-01

16

3.79E-01

 

Toll-like receptor signaling

62

17

5.75E-02

15

9.55E-02

11

7.76E-02

Cytokine signaling

IL-17A signaling in airway cells

72

21

1.35E-02

2

8.51E-02

11

1.58E-01

 

Prolactin signaling

80

22

3.72E-02

22

1.45E-02

17

6.46E-03

Cancer

Glioma signaling

112

29

1.55E-02

27

1.62E-02

19

2.14E-02

 

p53 signaling

96

32

1.48E-03

27

1.23E-02

20

8.51E-03

 

Small cell lung cancer signaling

89

27

6.03E-04

26

3.63E-04

20

2.57E-04

Cellular growth, proliferation and development

Cleavage and polyadenylation of pre-mRNA

12

5

8.32E-02

5

6.03E-02

4

5.01E-02

 

EGF signaling

62

21

2.88E-03

20

2.34E-03

13

1.66E-02

 

FAK signaling

101

27

1.32E-02

26

9.33E-03

17

3.47E-02

 

JAK/Stat signaling

70

26

5.37E-04

24

8.71E-04

20

1.07E-04

 

Oncostatin M signaling

35

12

3.55E-02

11

4.47E-02

8

5.01E-02

 

PDGF signaling

85

25

1.07E-02

24

6.92E-03

18

5.01E-03

 

Thrombopoietin signaling

63

17

4.90E-02

17

2.29E-02

12

3.31E-02

 

VEGF signaling

103

25

7.59E-02

25

3.47E-02

16

9.55E-02

Cell cycle regulation

Cyclins and cell cycle regulation

89

24

2.75E-02

23

2.19E-02

13

1.80E-01

 

GADD45 signaling

22

9

8.51E-03

8

2.40E-02

4

2.26E-01

 

Mitotic roles of polo-like kinase

70

18

1.39E-01

18

7.24E-02

9

4.44E-01

Growth Ffactor signaling

ErbB2-ErbB3 signaling

60

19

1.82E-02

19

7.08E-03

15

3.02E-03

Apoptosis

April mediated signaling

43

13

3.72E-02

11

9.12E-02

6

3.24E-01

 

Aryl hydrocarbon receptor signaling

161

40

1.48E-02

34

6.92E-02

21

1.96E-01

 

Myc mediated apoptosis signaling

60

20

1.05E-02

19

8.71E-03

14

9.33E-03

Cellular stress and injury

Endoplasmic reticulum stress pathway

18

7

6.03E-02

7

3.98E-02

4

1.73E-01

Disease-specific pathways

Parkinson’s signaling

16

4

4.32E-01

4

3.61E-01

-

-

Neurotransmitters and other nervous system signaling

Cholecystokinin/gastrin-mediated signaling

106

24

2.59E-01

20

4.56E-01

-

-

  1. bold: with statistical significance.